Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Zhejiang East Asia Pharmaceutical Co. Ltd. ¥8.81, price ¥28.29, upside -68.9%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ¥14.32 – ¥35.52 · fair‑value band ¥5.00 – ¥12.61 · the ¥28.29 price screens above the ¥8.81 fair value. Dashed = 300-day average. As of Oct 1, 2026.
Follow Zhejiang East Asia Pharmaceutical Co. in your weekly email
Every Wednesday you see whether Zhejiang East Asia Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules.
Show more
Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company provides products in the fields of cardiovascular, anti-aging dementia, digestive system, diabetic neuropathy, and anti-pathogenic microorganisms. It serves customers through a sales network in Japan, South Korea, Europe, America, Southeast Asia, and internationally. Zhejiang East Asia Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Taizhou, China.
Stock analysis
Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) currently trades at ¥28.29, while our model-based Fair Value estimate is ¥8.81, 68.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥10.80 per share, and 0 of the 4 models we run sit above the ¥28.29 price.
Bear case: the Asset-Based group reads lowest at ¥10.55, and 4 of the 4 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥5.00 (bear) to ¥12.61 (bull), the price of ¥28.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Zhejiang East Asia Pharmaceutical Co. Ltd. reported revenue of 940M CNY in FY2025 versus 712M CNY in FY2021, a compound +7.2%/yr. Reported net income was −82.4M CNY in FY2025.
Key figures
Market cap 3.2B CNY (≈ $486M) · P/S ratio 2.81 · EPS (TTM) ¥−1.49 · Dividend yield 0.3% · Net margin −8.8% · Return on equity −9.6% · Return on assets (EBIT) 1.7% · Operating margin −49.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 98% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −69%, 605177 screens richer than that median.
Fair Value models
Bear ¥5.00Fair Value ¥8.81Bull ¥12.61
Price ¥28.29 · Upside -68.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.8/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−21.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.2% (2020) → −3.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Zhejiang East Asia Pharmaceutical Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 587 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside−68.9% · Below median
Profitability
Return on assets−3.2% · Above median
Net margin (TTM)−17.2% · Below median
Operating margin (TTM)−49.1% · Bottom 25%
Growth and dividend
Revenue growth−10.4% · Below median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.27× · Cheapest 25%
P/S (TTM)0.49× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)79· sector 97
DIVIDEND (yield)6· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang East Asia Pharmaceutical Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/605177
Frequently asked questions
Is Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ¥8.81 versus a price of ¥28.29, about −69% upside (overvalued).
What is the fair value of 605177?
Our model-based fair value for Zhejiang East Asia Pharmaceutical Co. Ltd. is ¥8.81 (as of Oct 1, 2026), built from audited fundamentals. The current price: ¥28.29.
What is the quality score of 605177?
Zhejiang East Asia Pharmaceutical Co. Ltd. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
Our model-based price target is the fair value of ¥8.81 (as of Oct 1, 2026) from 4 valuation models. Cautious scenario ¥5.00, optimistic scenario ¥12.61. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang East Asia Pharmaceutical Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥8.81, about −69% upside versus a price of ¥28.29 (overvalued). Cautious scenario ¥5.00, optimistic scenario ¥12.61. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
Zhejiang East Asia Pharmaceutical Co. Ltd. reported trailing-twelve-month revenue of about 990M CNY (latest available figure, as of Oct 1, 2026).
Does Zhejiang East Asia Pharmaceutical Co. Ltd. pay a dividend?
Zhejiang East Asia Pharmaceutical Co. Ltd. currently shows a dividend yield of about 0.31% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang East Asia Pharmaceutical Co. Ltd. it is ¥8.81 per share (as of Oct 1, 2026), against a price of ¥28.29. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang East Asia Pharmaceutical Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 605177 trades above its calculated fair value: price ¥28.29, fair value ¥8.81, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 605177?
No. The price is what the market pays today (¥28.29); the fair value is what the company's own numbers justify (¥8.81). For Zhejiang East Asia Pharmaceutical Co. Ltd. the two are ¥19.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang East Asia Pharmaceutical Co. Ltd. worth?
The market values Zhejiang East Asia Pharmaceutical Co. Ltd. at about 3.2B CNY (market capitalisation, as of Oct 1, 2026). Per share that is ¥28.29; our models calculate a fair value of ¥8.81 per share.
What do the bullish and bearish scenarios say about 605177?
Our models span a range for Zhejiang East Asia Pharmaceutical Co. Ltd.: cautious scenario ¥5.00, base ¥8.81, optimistic ¥12.61 per share (as of Oct 1, 2026, price ¥28.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
Balance-sheet figures for Zhejiang East Asia Pharmaceutical Co. Ltd. (as of Oct 1, 2026): return on equity −9.6%, debt of 0.42 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 605177 from its 52-week high?
Zhejiang East Asia Pharmaceutical Co. Ltd. trades at ¥28.29, at its 52-week high of ¥28.29 and 98% above the low of ¥14.32 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥8.81 is for.
Which stocks are comparable to Zhejiang East Asia Pharmaceutical Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang East Asia Pharmaceutical Co. Ltd. stock attractive at the current price?
The data as of Oct 1, 2026: price ¥28.29, calculated fair value ¥8.81 (−69%), Quality Score 43/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 605177 calculated?
We run Zhejiang East Asia Pharmaceutical Co. Ltd. through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥8.81, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Zhejiang East Asia Pharmaceutical Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The closing price on Oct 9, 2026 was ¥28.29. Our model-based fair value is ¥8.81, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang East Asia Pharmaceutical Co. Ltd. right now?
The price sits above even our optimistic bull case (¥12.61). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥5.00 to ¥12.61) leaves room in how you read the outcome.
Key figures of Zhejiang East Asia Pharmaceutical Co. Ltd.
How large is the market capitalisation of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The market capitalisation of Zhejiang East Asia Pharmaceutical Co. Ltd. is 3.2B CNY (≈ $486M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The price-to-sales ratio of Zhejiang East Asia Pharmaceutical Co. Ltd. is 2.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
Earnings per share at Zhejiang East Asia Pharmaceutical Co. Ltd. are ¥−1.49. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The dividend yield of Zhejiang East Asia Pharmaceutical Co. Ltd. is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The net margin of Zhejiang East Asia Pharmaceutical Co. Ltd. is −8.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The return on equity (ROE) of Zhejiang East Asia Pharmaceutical Co. Ltd. is −9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
On an EBIT basis the return on assets of Zhejiang East Asia Pharmaceutical Co. Ltd. is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
The operating margin of Zhejiang East Asia Pharmaceutical Co. Ltd. is −49.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang East Asia Pharmaceutical Co. Ltd. (605177)?
Revenue at Zhejiang East Asia Pharmaceutical Co. Ltd. is growing −10.4% versus a year earlier (3y avg −7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) generate?
The free cash flow of Zhejiang East Asia Pharmaceutical Co. Ltd. is −343M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) carry?
The net debt of Zhejiang East Asia Pharmaceutical Co. Ltd. is 737M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhejiang East Asia Pharmaceutical Co. Ltd. in the live analysis
One click puts Zhejiang East Asia Pharmaceutical Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
